Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/pathology.1.005
Pancytopenia: An Update
Subhashish Das1,*
- 1Professor, Department of Pathology, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka, India
Corresponding Author
Subhashish Das, daspathology@gmail.com
Received Date: August 05, 2020
Accepted Date: September 02, 2020
Das S. Pancytopenia: An Update. J Exp Pathol 2020; 1(1): 28-32.
Copyright: © 2020 Das S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Kv1.3 Potassium Channels: Promising Therapeutic Targets in Hematological Malignancies
Voltage-gated Kv1.3 potassium channels control the membrane potential, cellular activation and cell death. Kv1.3 channels have been extensively studied in autoimmune disorders and are promising drug targets for the treatment of solid cancer.
The Role of Anemia in Term and Preterm Pregnancies: Evidence from the Brazilian Multicenter Study on Preterm Birth (EMIP)
Evaluate the prevalence of anemia in term and preterm pregnancies and compare maternal and perinatal outcomes among groups.
Is Platelet Desialylation a Novel Biomarker and Therapeutic Target in Immune Thrombocytopenia?
Platelets are small anuclear cells shed from the megakaryocyte, at a rate of ~1011/day [1], maintaining a blood concentration of 100-450 x 109/L in healthy adults. As the second most abundant circulating cells, they are becoming increasingly recognized for their versatility and cross-talks in cancer, development, immunology among others.
Needed, Assays for “Fetal Hemoglobin levels” in RBCs: Fetomaternal Hemorrhage and Expanded Applications in Sickle Cell Disease Management Could Forge an Evolution in Cellular Diagnostics
Treatment of sickle cell disease (SCD) remains varied with only a minority of patients benefiting from stem cell transplant as a near cure. Others await the promise of more effective and less toxic treatments than hydroxyurea, especially children who are most susceptible to the morbidities and mortalities of SCD. The recent report of Hebert, Rakotoson et al. points to an evolution of in vitro diagnostics (IVD) testing of blood cells with the emerging need for cell-by-cell measurement of red blood cell (RBC) specific hemoglobin variant levels. The study further provides clinical validation as to the utility of measuring HbF content in RBCs of SCD patients, not just as a prognostic test, but likely serving as a companion diagnostic in phase 3 clinical trials of new SCD therapies.
A Rare Blood Malignancy in a Genetic Hematological Disorder: Polycythemia Vera (PV) in Sickle Cell Disease (SCD)
To delineate the etiology, symptomatology, and treatment of Polycythemia Vera in adults with Sickle Cell Disease. The current review contains a review of the 4 case reports that we found on the topic. To our knowledge, no other case reports exist.